A novel chimeric drug candidate for treatment of human metastatic melanoma
A novel molecular chimera, CM358, for the treatment of a variety of cancers and specifically in treating human metastatic melanoma. The drug effectively inhibits human metastatic melanoma growth of tumor in xenograft model while exhibiting high survival rate without reduction of weight. This technology addresses a $1B drug market.
Novel Drugs Targeting Inflammatory Pathologies Based on a Core-Technology-Platform
Members of the Platform constitute families of complexes, each synthesized from 2 components. Each Member of the Platform is a potent anti-inflammatory agent, strong iron chelator, and antibiotic agent. Jointly, these 3 synergistic-parallel Mechanisms Of Action ensure therapeutic effectiveness in treating symptoms and causes of multiple indications.
Inventors at Georgia Tech and the University of Colorado have developed a method to capture sites of rNMP incorporation in genomic DNA. The method allows the analysis of the sites of rNMP incorporation with high-throughput sequencing and identification of the profile of rNMP incorporation in genomic DNA.
Screening Method for the Anti-Cancer Substance Hindering the Functions of TMF4SF5 and the Anti-Cancer Composite Containing Chalcone Compound
Screening method for TMF4SF5 anti-cancer substance and the anti-cancer composite using this. This compound improves functions of the anti-cancer compound and reduces external damage and toxic reaction to maximize the anti-cancer effect by screening the substances that hinder production and transition of several cancer cells.
New York, NY
A platform technology to activate a targeted immune response to selected tumor types
Our technology activates and targets two immune responses to attack, infiltrate and destroy tumors. It works by selectively activating dendritic cells (which control the immune sytem) and targeting their response to cells that present a cancer specific protein. We can engineer this response to any protein, therefore many different tumors.
Novel HIV vaccine
This recombinant vaccine optimises anti-viral host responses, both in mucosal tissue and systemically, using a new adjuvant strategy and delivery regimen. Currently in late preclinical trials, the vaccine shows strong potential for treatment and immunization against HIV. The strategy is a platform technology with applications against other intracellular pathogens.